uniQure (NASDAQ:QURE) Announces Quarterly Earnings Results

Key Points

• uniQure reported a quarterly EPS of ($0.69), exceeding analysts' expectations by $0.20, which were revised to ($0.89).
• The company has been rated as a "Moderate Buy" by analysts, with a consensus target price of $37.82.
• Recent insider transactions included the sale of shares by directors, with 22,144 shares sold in the last 90 days, signaling a decrease in insider ownership.

uniQure (NASDAQ:QURE - Get Free Report) announced its earnings results on Tuesday. The biotechnology company reported ($0.69) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.89) by $0.20, Zacks reports. The business had revenue of $5.26 million for the quarter, compared to analysts' expectations of $5.00 million. uniQure had a negative return on equity of 1,010.74% and a negative net margin of 1,387.98%.

uniQure Stock Performance

Shares of NASDAQ QURE traded down $0.23 during trading on Friday, reaching $13.69. 1,062,536 shares of the company traded hands, compared to its average volume of 1,428,015. The firm's fifty day simple moving average is $14.86 and its 200 day simple moving average is $13.68. The stock has a market cap of $751.17 million, a P/E ratio of -3.49 and a beta of 0.08. uniQure has a 12-month low of $4.45 and a 12-month high of $19.18. The company has a current ratio of 9.98, a quick ratio of 11.99 and a debt-to-equity ratio of 1.53.

Insider Buying and Selling at uniQure

In related news, Director David D. Meek sold 2,112 shares of uniQure stock in a transaction dated Friday, June 20th. The stock was sold at an average price of $14.45, for a total value of $30,518.40. Following the completion of the transaction, the director owned 34,190 shares in the company, valued at $494,045.50. The trade was a 5.82% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Jeannette Potts sold 4,670 shares of uniQure stock in a transaction dated Monday, June 16th. The shares were sold at an average price of $15.14, for a total value of $70,703.80. Following the completion of the transaction, the insider owned 115,073 shares of the company's stock, valued at approximately $1,742,205.22. This represents a 3.90% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 22,144 shares of company stock worth $322,426. Insiders own 4.79% of the company's stock.

Hedge Funds Weigh In On uniQure

A hedge fund recently raised its stake in uniQure stock. Woodline Partners LP lifted its holdings in uniQure N.V. (NASDAQ:QURE - Free Report) by 25.0% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 175,806 shares of the biotechnology company's stock after purchasing an additional 35,175 shares during the period. Woodline Partners LP owned about 0.32% of uniQure worth $1,864,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 78.83% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the company. Chardan Capital lowered their price objective on uniQure from $38.00 to $35.00 and set a "buy" rating for the company in a research report on Tuesday. Guggenheim reaffirmed a "buy" rating and set a $28.00 price target on shares of uniQure in a research report on Monday, May 12th. Wall Street Zen cut uniQure from a "hold" rating to a "sell" rating in a research report on Saturday, June 14th. HC Wainwright reaffirmed a "buy" rating and set a $70.00 price target on shares of uniQure in a research report on Thursday, May 29th. Finally, Cantor Fitzgerald set a $47.00 price target on uniQure in a research report on Wednesday. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, six have issued a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat.com, uniQure currently has an average rating of "Moderate Buy" and a consensus price target of $36.55.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.